Long, lustrous hair is a universal desire, but the journey to achieve it often leads people to the vitamin aisle. Shelves are ...

The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

Treatment with guselkumab among patients with psoriasis does not contribute to the risk for or progression of liver fibrosis.

Guselkumab treatment was associated with improvements in 3 biomarkers associated with systemic inflammation among patients with plaque psoriasis.

Patients with psoriasis generally prefer the standard of care over teledermatology, but certain attributes change patient preferences.

For patients with genital psoriasis, apremilast improved genital Physician Global Assessment scores, itch, and quality of life with a tolerable safety profile.

Results from the separate SCALP study, involving 102 patients with moderate-to-severe scalp psoriasis, showed a significantly higher proportion of patients receiving Cosentyx had 90% plaque ...

"Plaque psoriasis often affects patients more severely than can be measured by body surface area alone, particularly for those with manifestations in difficult-to-treat areas like the scalp," she ...